EDGE - Edge Therapeutics Stock Price, News & Analysis

$9.90 0.11 (1.12 %)
(As of 11/22/2017 04:00 PM ET)
Previous Close$9.79
Today's Range$9.72 - $10.15
52-Week Range$7.30 - $13.50
Volume53,888 shs
Average Volume63,432 shs
Market Capitalization$292.85 million
P/E RatioN/A
Dividend YieldN/A
Beta2.69

About Edge Therapeutics (NASDAQ:EDGE)

Edge Therapeutics logoEdge Therapeutics, Inc. is a clinical-stage biotechnology company that discovers, develops and seeks to commercialize hospital-based therapies capable of transforming treatment paradigms in the management of acute, life-threatening critical care conditions. The Company's initial product candidates target rare, acute, life-threatening neurological and other conditions. The Company's product candidates utilize its programmable, biodegradable polymer-based development platform (the Precisa Platform), a delivery mechanism that seeks to enable targeted and sustained drug exposure and avoid the dose-limiting side effects associated with the current standards of care. The Company's product candidates include EG-1962 and EG-1964. EG-1962 is a polymer-based microsphere containing nimodipine suspended in a diluent of sodium hyaluronate was developed using its Precisa development platform to improve patient outcomes following aneurysmal subarachnoid hemorrhage (aSAH).


Industry, Sector and Symbol:
  • Industry: Bio Therapeutic Drugs
  • Sub-Industry: N/A
  • Sector: Medical
  • Symbol: NASDAQ:EDGE
  • CUSIP: N/A
  • Web: www.edgetherapeutics.com
Debt:
  • Debt-to-Equity Ratio: 0.20%
  • Current Ratio: 8.34%
  • Quick Ratio: 8.34%
Sales & Book Value:
  • Annual Sales: N/A
  • Price / Sales: N/A
  • Book Value: $2.42 per share
  • Price / Book: 4.09
Profitability:
  • Trailing EPS: ($1.56)
  • Net Income: $-38,820,000.00
  • Return on Equity: -56.88%
  • Return on Assets: -43.74%
Misc:
  • Employees: 31
  • Outstanding Shares: 30,860,000
 

Frequently Asked Questions for Edge Therapeutics (NASDAQ:EDGE)

What is Edge Therapeutics' stock symbol?

Edge Therapeutics trades on the NASDAQ under the ticker symbol "EDGE."

How were Edge Therapeutics' earnings last quarter?

Edge Therapeutics, Inc. (NASDAQ:EDGE) issued its quarterly earnings results on Wednesday, November, 1st. The biotechnology company reported ($0.37) EPS for the quarter, topping the consensus estimate of ($0.48) by $0.11. View Edge Therapeutics' Earnings History.

Where is Edge Therapeutics' stock going? Where will Edge Therapeutics' stock price be in 2017?

2 Wall Street analysts have issued 12 month price objectives for Edge Therapeutics' stock. Their predictions range from $21.00 to $30.00. On average, they anticipate Edge Therapeutics' stock price to reach $25.50 in the next year. View Analyst Ratings for Edge Therapeutics.

Who are some of Edge Therapeutics' key competitors?

Who are Edge Therapeutics' key executives?

Edge Therapeutics' management team includes the folowing people:

  • Sol J. Barer Ph.D., Independent Chairman of the Board (Age 69)
  • Brian A. Leuthner, President, Chief Executive Officer, Director (Age 52)
  • Isaac Blech, Independent Vice Chairman of the Board (Age 67)
  • Andrew Saik, Chief Financial Officer (Age 48)
  • Daniel Brennan, Chief Operating Officer (Age 49)
  • W. Bradford Middlekauff, Senior Vice President, General Counsel, Secretary (Age 55)
  • Alyssa J. S. Wyant, Senior Vice President, Regulatory Affairs (Age 42)
  • Albert N. Marchio II, Chief Accounting Officer, Chief Administrative Officer (Age 64)
  • R. Loch Macdonald M.D. Ph.D., Chief Scientific Officer, Director (Age 55)
  • Herbert J. Faleck, Chief Medical Officer (Age 64)

Who owns Edge Therapeutics stock?

Edge Therapeutics' stock is owned by many different of retail and institutional investors. Top institutional investors include Janus Henderson Group PLC (6.79%), VHCP Management II LLC (4.15%), Eagle Asset Management Inc. (2.74%), JPMorgan Chase & Co. (1.23%), Sphera Funds Management LTD. (1.08%) and Regentatlantic Capital LLC (0.36%). Company insiders that own Edge Therapeutics stock include Albert N Marchio II, Brian A Leuthner, James Healy, James J Loughlin and W Bradford Middlekauff. View Institutional Ownership Trends for Edge Therapeutics.

Who sold Edge Therapeutics stock? Who is selling Edge Therapeutics stock?

Edge Therapeutics' stock was sold by a variety of institutional investors in the last quarter, including VHCP Management II LLC, Eagle Asset Management Inc., Janus Henderson Group PLC and Regentatlantic Capital LLC. Company insiders that have sold Edge Therapeutics company stock in the last year include Albert N Marchio II and Brian A Leuthner. View Insider Buying and Selling for Edge Therapeutics.

Who bought Edge Therapeutics stock? Who is buying Edge Therapeutics stock?

Edge Therapeutics' stock was bought by a variety of institutional investors in the last quarter, including JPMorgan Chase & Co., Sphera Funds Management LTD., Trexquant Investment LP and Wells Fargo & Company MN. Company insiders that have bought Edge Therapeutics stock in the last two years include James Healy, James J Loughlin and W Bradford Middlekauff. View Insider Buying and Selling for Edge Therapeutics.

How do I buy Edge Therapeutics stock?

Shares of Edge Therapeutics can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Edge Therapeutics' stock price today?

One share of Edge Therapeutics stock can currently be purchased for approximately $9.90.

How big of a company is Edge Therapeutics?

Edge Therapeutics has a market capitalization of $292.85 million. The biotechnology company earns $-38,820,000.00 in net income (profit) each year or ($1.56) on an earnings per share basis. Edge Therapeutics employs 31 workers across the globe.

How can I contact Edge Therapeutics?

Edge Therapeutics' mailing address is 300 Connell Drive Suite 4000, Berkeley Heights NJ, 07922. The biotechnology company can be reached via phone at 800-208-3343 or via email at [email protected]


MarketBeat Community Rating for Edge Therapeutics (EDGE)

Community Ranking:  2.4 out of 5 (star star)
Outperform Votes:  69 (Vote Outperform)
Underperform Votes:  74 (Vote Underperform)
Total Votes:  143
MarketBeat's community ratings are surveys of what our community members think about Edge Therapeutics and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Analysts' Consensus Rating for Edge Therapeutics (NASDAQ:EDGE)

  (How are Consensus Ratings Calculated?)
Ratings Breakdown: 0 Sell Ratings, 1 Hold Rating, 1 Buy Rating, 0 Strong Buy Ratings
Consensus Rating:Buy (Score: 2.50)
Consensus Price Target: $25.50 (157.58% upside)

Consensus Price Target History for Edge Therapeutics (NASDAQ:EDGE)

Price Target History for Edge Therapeutics (NASDAQ:EDGE)

Analysts' Ratings History for Edge Therapeutics (NASDAQ:EDGE)

Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
3/3/2017Leerink SwannReiterated RatingOutperform -> Outperform$21.00N/AView Rating Details
3/3/2017GuggenheimReiterated RatingBuy -> In-Line$30.00N/AView Rating Details
5/9/2016Credit Suisse GroupLower Price TargetOutperform$19.00 -> $18.00N/AView Rating Details
3/9/2016JMP SecuritiesLower Price TargetMarket Outperform$34.00 -> $18.00N/AView Rating Details
(Data available from 11/22/2015 forward)

Earnings

Earnings History and Estimates Chart for Edge Therapeutics (NASDAQ:EDGE)

Earnings by Quarter for Edge Therapeutics (NASDAQ:EDGE)

Earnings History by Quarter for Edge Therapeutics (NASDAQ EDGE)

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/1/2017Q3 2017($0.48)($0.37)ViewN/AView Earnings Details
8/1/2017Q2 2017($0.44)($0.44)ViewListenView Earnings Details
5/3/2017Q1 2017($0.42)($0.42)ViewListenView Earnings Details
3/2/2017Q4 2016($0.42)($0.33)ViewListenView Earnings Details
8/3/2016Q2($0.38)($0.33)ViewListenView Earnings Details
5/3/2016Q1 2016($0.34)($0.32)ViewListenView Earnings Details
3/8/2016Q4($0.32)($0.30)ViewListenView Earnings Details
11/6/2015Q315($0.23)($7.08)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Edge Therapeutics (NASDAQ:EDGE)
2017 EPS Consensus Estimate: ($1.82)
2018 EPS Consensus Estimate: ($2.11)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20171($0.42)($0.42)($0.42)
Q2 20171($0.45)($0.45)($0.45)
Q3 20171($0.48)($0.48)($0.48)
Q4 20171($0.47)($0.47)($0.47)
Q1 20181($0.55)($0.55)($0.55)
Q2 20181($0.52)($0.52)($0.52)
Q3 20181($0.51)($0.51)($0.51)
Q4 20181($0.53)($0.53)($0.53)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Edge Therapeutics (NASDAQ:EDGE)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Edge Therapeutics (NASDAQ EDGE)

Insider Ownership Percentage: 36.19%
Institutional Ownership Percentage: 50.53%
Insider Trades by Quarter for Edge Therapeutics (NASDAQ:EDGE)
Institutional Ownership by Quarter for Edge Therapeutics (NASDAQ:EDGE)

Insider Trades by Quarter for Edge Therapeutics (NASDAQ EDGE)

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
11/22/2017Albert N. Marchio IIInsiderSell3,361$10.00$33,610.00View SEC Filing  
11/3/2017Brian A LeuthnerInsiderSell7,500$10.91$81,825.00View SEC Filing  
11/1/2017Brian A LeuthnerCEOSell2,500$10.92$27,300.00View SEC Filing  
10/4/2017Brian A LeuthnerInsiderSell7,500$10.96$82,200.00View SEC Filing  
10/3/2017Brian A LeuthnerCEOSell2,500$10.93$27,325.00View SEC Filing  
10/2/2017Brian A LeuthnerCEOSell2,500$10.81$27,025.00View SEC Filing  
9/6/2017Brian A LeuthnerInsiderSell7,500$10.21$76,575.00View SEC Filing  
9/5/2017Brian A LeuthnerCEOSell2,500$9.94$24,850.00View SEC Filing  
9/1/2017Brian A LeuthnerCEOSell2,500$10.37$25,925.00View SEC Filing  
8/29/2017Albert N Marchio IIInsiderSell2,500$10.42$26,050.00View SEC Filing  
8/23/2017Albert N Marchio IIInsiderSell1,000$10.39$10,390.00View SEC Filing  
8/3/2017Brian A LeuthnerInsiderSell7,500$10.53$78,975.00View SEC Filing  
7/6/2017Brian A LeuthnerInsiderSell7,500$10.19$76,425.00View SEC Filing  
3/6/2017James J LoughlinDirectorBuy3,000$9.24$27,720.00View SEC Filing  
2/7/2017Brian A LeuthnerInsiderSell1,500$9.52$14,280.00View SEC Filing  
2/6/2017Brian A LeuthnerInsiderSell3,000$9.61$28,830.00View SEC Filing  
2/2/2017Brian A LeuthnerInsiderSell3,000$9.50$28,500.00View SEC Filing  
12/1/2016Brian A LeuthnerInsiderSell7,500$11.60$87,000.00View SEC Filing  
10/3/2016Brian A LeuthnerInsiderSell7,500$10.25$76,875.00View SEC Filing  
8/8/2016W Bradford MiddlekauffVPBuy10,000$9.48$94,800.00View SEC Filing  
8/1/2016Brian A LeuthnerInsiderSell7,500$9.54$71,550.00View SEC Filing  
3/11/2016James HealyDirectorBuy541,343$7.30$3,951,803.90View SEC Filing  
10/6/2015Andrew J. EinhornCFOBuy45,000$11.00$495,000.00View SEC Filing  
10/6/2015James HealyDirectorBuy450,000$11.00$4,950,000.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for Edge Therapeutics (NASDAQ EDGE)

Source:
DateHeadline
Albert N. Marchio II Sells 3,361 Shares of Edge Therapeutics, Inc. (EDGE) StockAlbert N. Marchio II Sells 3,361 Shares of Edge Therapeutics, Inc. (EDGE) Stock
www.americanbankingnews.com - November 22 at 4:54 PM
Brokerages Anticipate Edge Therapeutics, Inc. (EDGE) to Announce ($0.47) Earnings Per ShareBrokerages Anticipate Edge Therapeutics, Inc. (EDGE) to Announce ($0.47) Earnings Per Share
www.americanbankingnews.com - November 18 at 7:24 PM
Edge Therapeutics (EDGE) and Affimed N.V. (AFMD) Head-To-Head ComparisonEdge Therapeutics (EDGE) and Affimed N.V. (AFMD) Head-To-Head Comparison
www.americanbankingnews.com - November 18 at 3:37 AM
Mid-Morning Market Update: Markets Edge Lower; Tyson Foods Tops Q4 ExpectationsMid-Morning Market Update: Markets Edge Lower; Tyson Foods Tops Q4 Expectations
www.nasdaq.com - November 13 at 11:45 AM
Zacks Investment Research Upgrades Edge Therapeutics, Inc. (EDGE) to "Buy"Zacks Investment Research Upgrades Edge Therapeutics, Inc. (EDGE) to "Buy"
www.americanbankingnews.com - November 6 at 11:36 PM
Edge Therapeutics to Present at the 26th Annual Credit Suisse Healthcare ConferenceEdge Therapeutics to Present at the 26th Annual Credit Suisse Healthcare Conference
finance.yahoo.com - November 6 at 7:36 PM
FY2017 EPS Estimates for Edge Therapeutics, Inc. Raised by Leerink Swann (EDGE)FY2017 EPS Estimates for Edge Therapeutics, Inc. Raised by Leerink Swann (EDGE)
www.americanbankingnews.com - November 6 at 6:14 AM
Edge Therapeutics, Inc. (EDGE) CEO Sells $27,300.00 in StockEdge Therapeutics, Inc. (EDGE) CEO Sells $27,300.00 in Stock
www.americanbankingnews.com - November 3 at 9:44 PM
Insider Selling: Edge Therapeutics, Inc. (EDGE) Insider Sells 7,500 Shares of StockInsider Selling: Edge Therapeutics, Inc. (EDGE) Insider Sells 7,500 Shares of Stock
www.americanbankingnews.com - November 3 at 9:24 PM
Obalon Therapeutics, Inc. And Sono Bello Announce Agreement To Offer Novel Weight Loss Treatment In Sono Bello CentersObalon Therapeutics, Inc. And Sono Bello Announce Agreement To Offer Novel Weight Loss Treatment In Sono Bello Centers
www.thestreet.com - November 3 at 1:20 PM
Edge Therapeutics, Inc. (EDGE) Issues  Earnings ResultsEdge Therapeutics, Inc. (EDGE) Issues Earnings Results
www.americanbankingnews.com - November 2 at 3:07 PM
Edited Transcript of EDGE earnings conference call or presentation 1-Nov-17 12:30pm GMTEdited Transcript of EDGE earnings conference call or presentation 1-Nov-17 12:30pm GMT
finance.yahoo.com - November 2 at 12:10 AM
Edge Therapeutics Reports Third Quarter 2017 Financial ResultsEdge Therapeutics Reports Third Quarter 2017 Financial Results
finance.yahoo.com - November 1 at 7:08 PM
Edge Therapeutics reports 3Q lossEdge Therapeutics reports 3Q loss
finance.yahoo.com - November 1 at 7:08 PM
Is Edge Therapeutics Inc’s (EDGE) Balance Sheet A Threat To Its Future?Is Edge Therapeutics Inc’s (EDGE) Balance Sheet A Threat To Its Future?
finance.yahoo.com - November 1 at 7:08 PM
Analyzing Edge Therapeutics (EDGE) and Ardelyx (ARDX)Analyzing Edge Therapeutics (EDGE) and Ardelyx (ARDX)
www.americanbankingnews.com - November 1 at 5:12 PM
Ortek Therapeutics, Inc. Announces FDA Clearance For Breakthrough Electronic Cavity Detection DeviceOrtek Therapeutics, Inc. Announces FDA Clearance For Breakthrough Electronic Cavity Detection Device
finance.yahoo.com - October 25 at 2:08 AM
Osiris Announces A Peer-Reviewed Publication Of A Scientific Study Reporting Antimicrobial Properties Of Human Cryopreserved Viable Amniotic MembraneOsiris Announces A Peer-Reviewed Publication Of A Scientific Study Reporting Antimicrobial Properties Of Human Cryopreserved Viable Amniotic Membrane
www.thestreet.com - October 24 at 1:52 AM
Your Daily Pharma Scoop: Adamis Upside Potential, J&Js SIMPONI Label Expansion, SGENs Adcetris Upgrade And PDUFAYour Daily Pharma Scoop: Adamis Upside Potential, J&J's SIMPONI Label Expansion, SGEN's Adcetris Upgrade And PDUFA
seekingalpha.com - October 23 at 3:50 PM
Edge Therapeutics, Inc. (EDGE) Scheduled to Post Quarterly Earnings on MondayEdge Therapeutics, Inc. (EDGE) Scheduled to Post Quarterly Earnings on Monday
www.americanbankingnews.com - October 23 at 9:00 AM
Edge Therapeutics, Inc. (EDGE) Expected to Announce Earnings of -$0.48 Per ShareEdge Therapeutics, Inc. (EDGE) Expected to Announce Earnings of -$0.48 Per Share
www.americanbankingnews.com - October 20 at 12:32 AM
Edge Therapeutics Announces Third Quarter Financial Results Conference Call on November 1, 2017Edge Therapeutics Announces Third Quarter Financial Results Conference Call on November 1, 2017
finance.yahoo.com - October 18 at 7:31 PM
Spark Therapeutics: Inside The Dramatic FDA AdCom MeetingSpark Therapeutics: Inside The Dramatic FDA AdCom Meeting
finance.yahoo.com - October 13 at 11:41 PM
Edge Therapeutics to Present at the Neurocritical Care Society 15th Annual MeetingEdge Therapeutics to Present at the Neurocritical Care Society 15th Annual Meeting
finance.yahoo.com - October 6 at 9:03 AM
Edge Therapeutics Inc (EDGE) CEO Brian A. Leuthner Sells 2,500 SharesEdge Therapeutics Inc (EDGE) CEO Brian A. Leuthner Sells 2,500 Shares
www.americanbankingnews.com - October 4 at 8:48 PM
Edge Therapeutics Inc (EDGE) CEO Sells $27,325.00 in StockEdge Therapeutics Inc (EDGE) CEO Sells $27,325.00 in Stock
www.americanbankingnews.com - October 4 at 8:46 PM
Insider Selling: Edge Therapeutics Inc (EDGE) Insider Sells 7,500 Shares of StockInsider Selling: Edge Therapeutics Inc (EDGE) Insider Sells 7,500 Shares of Stock
www.americanbankingnews.com - October 4 at 8:46 PM
BlueRock Therapeutics and Universal Cells Enter Collaboration and License Agreement to Generate Gene-Edited iPS Cell LinesBlueRock Therapeutics and Universal Cells Enter Collaboration and License Agreement to Generate Gene-Edited iPS Cell Lines
www.bizjournals.com - October 3 at 6:03 PM
Analyzing Edge Therapeutics (EDGE) and bluebird bio (BLUE)Analyzing Edge Therapeutics (EDGE) and bluebird bio (BLUE)
www.americanbankingnews.com - October 3 at 8:26 AM
Edge Therapeutics to Present at Upcoming Investor ConferencesEdge Therapeutics to Present at Upcoming Investor Conferences
finance.yahoo.com - September 20 at 7:01 PM
BRIEF-Edge Therapeutics appoints Rosemary Crane to Board of DirectorsBRIEF-Edge Therapeutics appoints Rosemary Crane to Board of Directors
www.reuters.com - September 19 at 11:07 PM
Edge Therapeutics Appoints Rosemary A. Crane, Pharmaceutical Industry Leader, to its Board of DirectorsEdge Therapeutics Appoints Rosemary A. Crane, Pharmaceutical Industry Leader, to its Board of Directors
finance.yahoo.com - September 19 at 6:07 PM
Leerink Swann Comments on Edge Therapeutics, Inc.s FY2017 Earnings (EDGE)Leerink Swann Comments on Edge Therapeutics, Inc.'s FY2017 Earnings (EDGE)
www.americanbankingnews.com - September 8 at 6:50 AM
Insider Selling: Edge Therapeutics, Inc. (EDGE) CEO Sells 2,500 Shares of StockInsider Selling: Edge Therapeutics, Inc. (EDGE) CEO Sells 2,500 Shares of Stock
www.americanbankingnews.com - September 6 at 10:46 PM
Insider Selling: Edge Therapeutics, Inc. (EDGE) CEO Sells 2,500 Shares of StockInsider Selling: Edge Therapeutics, Inc. (EDGE) CEO Sells 2,500 Shares of Stock
www.americanbankingnews.com - September 6 at 10:46 PM
Edge Therapeutics, Inc. (EDGE) Insider Sells $76,575.00 in StockEdge Therapeutics, Inc. (EDGE) Insider Sells $76,575.00 in Stock
www.americanbankingnews.com - September 6 at 10:26 PM
Navidea To Initiate Regular Webcast Series Featuring Moderated Q&A with ManagementNavidea To Initiate Regular Webcast Series Featuring Moderated Q&A with Management
www.businesswire.com - August 30 at 7:19 PM
Edge Therapeutics, Inc. (EDGE) Insider Albert N. Marchio II Sells 2,500 SharesEdge Therapeutics, Inc. (EDGE) Insider Albert N. Marchio II Sells 2,500 Shares
www.americanbankingnews.com - August 29 at 8:24 PM
Insider Selling: Edge Therapeutics, Inc. (EDGE) Insider Sells 1,000 Shares of StockInsider Selling: Edge Therapeutics, Inc. (EDGE) Insider Sells 1,000 Shares of Stock
www.americanbankingnews.com - August 24 at 8:23 PM
-$0.48 Earnings Per Share Expected for Edge Therapeutics, Inc. (EDGE) This Quarter-$0.48 Earnings Per Share Expected for Edge Therapeutics, Inc. (EDGE) This Quarter
www.americanbankingnews.com - August 6 at 12:28 PM
Edge Therapeutics, Inc. (EDGE) Insider Brian A. Leuthner Sells 7,500 SharesEdge Therapeutics, Inc. (EDGE) Insider Brian A. Leuthner Sells 7,500 Shares
www.americanbankingnews.com - August 3 at 10:56 PM
FY2018 EPS Estimates for Edge Therapeutics, Inc. (NASDAQ:EDGE) Lowered by Leerink SwannFY2018 EPS Estimates for Edge Therapeutics, Inc. (NASDAQ:EDGE) Lowered by Leerink Swann
www.americanbankingnews.com - August 3 at 3:32 PM
Edited Transcript of EDGE earnings conference call or presentation 1-Aug-17 12:30pm GMTEdited Transcript of EDGE earnings conference call or presentation 1-Aug-17 12:30pm GMT
finance.yahoo.com - August 2 at 7:02 PM
Edge Therapeutics, Inc. (NASDAQ:EDGE) Posts  Earnings Results, Hits ExpectationsEdge Therapeutics, Inc. (NASDAQ:EDGE) Posts Earnings Results, Hits Expectations
www.americanbankingnews.com - August 2 at 2:42 PM
Edge Therapeutics Reports Second Quarter 2017 Financial Results and Continued Operational ProgressEdge Therapeutics Reports Second Quarter 2017 Financial Results and Continued Operational Progress
finance.yahoo.com - August 1 at 6:49 PM
Edge Therapeutics reports 2Q lossEdge Therapeutics reports 2Q loss
finance.yahoo.com - August 1 at 6:49 PM
-$0.45 Earnings Per Share Expected for Edge Therapeutics, Inc. (NASDAQ:EDGE) This Quarter-$0.45 Earnings Per Share Expected for Edge Therapeutics, Inc. (NASDAQ:EDGE) This Quarter
www.americanbankingnews.com - July 17 at 11:31 AM
Edge Therapeutics, Inc. (EDGE) Insider Sells $76,425.00 in StockEdge Therapeutics, Inc. (EDGE) Insider Sells $76,425.00 in Stock
www.americanbankingnews.com - July 6 at 8:05 PM
European ADRs Edge Higher as Telecommunication Stocks AdvanceEuropean ADRs Edge Higher as Telecommunication Stocks Advance
www.nasdaq.com - May 12 at 5:22 PM
BRIEF-Edge Therapeutics Qtrly loss per share $0.42BRIEF-Edge Therapeutics Qtrly loss per share $0.42
www.reuters.com - May 3 at 4:47 PM

Social Media

Financials

Chart

Edge Therapeutics (NASDAQ EDGE) Chart for Wednesday, November, 22, 2017
Loading chart…

This page was last updated on 11/22/2017 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.